<DOC>
	<DOCNO>NCT00885690</DOCNO>
	<brief_summary>Cognition one core symptom schizophrenia . This study head-to-head trial olanzapine sertindole cognition primary outcome . The design 12-week double-blinded randomize control flexible dose study .</brief_summary>
	<brief_title>Comparing Effects Sertindole Olanzapine Cognition ( SEROLA )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Sertindole</mesh_term>
	<criteria>AnICD10 schizophrenia diagnosis F20.0F20.9 . Contraception . A negative pregnancy test woman . No known allergy substance study medication Baseline QTc &lt; 450 millisecond men &lt; 470 millisecond woman Spotassium smagnesium within normal reference range . Suboptimally treated current antipsychotic medication Stable dosage antidepressant mood stabilizer one month inclusion Signed informed consent power attorney Withdrawal consent QTc prolongation &gt; 500 millisecond study Patients know clinical important cardiovascular disease Significant substance abuse Earlier partial nonresponse treatment intolerability sertindole olanzapine . Calgary Depression Scale score â‰¥ 7 Treatment interferes metabolism sertindole olanzapine , Oxazepam , zopiclone zolpidem treatment last 48 hour cognitive test Prescription notallowed medication , change dosage antidepressant , mood stabilizer study period Treatment anticholinergic first three week study Somatic illness , judge investigator , interfere cognition Known risk narrow angle glaucoma Treatment electroconvulsive therapy ( ECT ) last three month inclusion , treatment ECT study period Treatment clozapine depot antipsychotic inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Antipsychotic</keyword>
	<keyword>Cognition</keyword>
</DOC>